Promoter polymorphism of MRP1 associated with reduced survival in hepatocellular carcinoma

Table 3 Multivariate analysis for prognostic value of multidrug resistance related protein-1 G-1666A polymorphism in patients with hepatocellular carcinoma

Genotypes	DFS1		OS2
	HR (95% CI)	Pa	HR (95% CI)	Pa
All (n = 162)
AA+AG	1
GG	3.067 (1.587-5.952)	0.001
Men (n = 147)
AA + AG	1		1
GG	3.154 (1.604-6.201)	0.001	3.342 (1.474-7.576)	0.004

^aHazard ratio (HR) and P values were calculated using multivariate Cox regression. P < 0.05 was considered to indicate statistical significance;

¹Multivariate analysis of disease-free survival (DFS) in all patients was adjusted for sex, γ-glutamyl transpeptidase (GGT), α-fetoprotein (AFP), tumor size, ascites, and TNM stage; in male patients, it was adjusted for GGT, tumor size, and TNM stage;

²Multivariate analysis of OS in male patients was adjusted for GGT, tumor size, ascites, cirrhosis, and TNM stage. OS: Overall survival; CI: Confidence interval.